- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01036490
Exercise in Obese Diabetic Patients With Chronic Kidney Disease (EX-ODCKD)
Structured Exercise in Obese Diabetic Patients With Chronic Kidney Disease
Studie Overzicht
Gedetailleerde beschrijving
Patients with type 2 diabetes, obesity, and chronic kidney disease (CKD) are generally physically inactive, have a high mortality rate, and may benefit from an exercise program. However, there have been no randomized controlled trials to determine the benefits of exercise training in this population. This study seeks to substantiate the hypothesis that increasing energy expenditure by exercise training in the obese diabetic patient with CKD will result in the following benefits:
- Renal benefits, including reduction in proteinuria and stabilization of glomerular filtration rate (GFR)
- Cardiovascular benefits, including decreased blood pressure, decreased heart rate, and increased exercise tolerance.
- Improved glucose control (lower glycated hemoglobin), lipid control (decreased cholesterol with improved atherogenic profile)
- Improved body composition (weight loss, increased lean body mass and decreased fat mass).
- Decreased inflammation (assessed by high-sensitivity C-reactive protein), endothelial dysfunction (assessed by flow-mediated dilatation), and oxidative stress (assessed by reduced glutathione).
- Increased health-related quality of life.
In preparation for this proposal, the investigators performed a 24-week randomized controlled feasibility study comparing aerobic exercise plus optimal medical management to medical management alone in patients with type 2 diabetes, obesity (BMI > 30 kg/m2), and stage 2-4 CKD (eGFR 15-90 mL/min/1.73m2) with persistent proteinuria of > 200 mg/g. Subjects randomized to exercise underwent thrice weekly aerobic training for 6 followed by 18 weeks of supervised home exercise. The primary outcome variable was change in proteinuria. Exercise training resulted in a significant improvement in exercise duration during stress testing which persisted until 24 weeks. This was accompanied by significant decreases in resting systolic blood pressure and 24-hour proteinuria at 24 weeks. No changes were seen in the control group. The investigators concluded that exercise training in obese diabetic patients with CKD is feasible and results in a demonstrable training effect (increased exercise duration and decreased resting blood pressure). Moreover, it may decrease proteinuria and thus have a renoprotective effect.
The investigators now propose a larger-scale randomized controlled trial to determine the effects of exercise on renal functions, cardiovascular fitness, inflammation, and oxidative stress in diabetic patients with CKD. This will be a 52-week randomized study based on the investigators' pilot study design with some modifications. As opposed to the 6-week training period and 18-week home exercise period utilized in the pilot study, subjects randomized to exercise will undergo 12 weeks of intensive exercise training in the exercise laboratory followed by 40 weeks of supervised home exercise training (total duration of study 1 year). Moreover, due to recent recommendations that resistance training be incorporated into exercise training regimens in type 2 diabetic patients, the investigators will incorporate resistance (strength) training in this proposal. The primary outcome variable will be change in proteinuria at 12 and 52 weeks. Secondary outcome variables will be change in albuminuria and estimated glomerular filtration rate (eGFR) at 12 and 52 weeks. In addition, the investigators will measure blood pressure (BP), glycated hemoglobin, lipid profile, C-reactive protein (CRP) levels, body weight and composition, endothelial dysfunction (by flow-mediated dilatation), and Quality of Life (QoL) evaluations. The Index of Coexistent Diseases (ICED) to measure comorbidities to determine if comorbid conditions had any influence on the outcomes of the study. The Center for Epidemiologic Studies Depression Scale (CES-D) will also be used to determine the influence of depression (covariate) on study outcomes and adherence with the study objectives.
This study will directly address the effects of a structured exercise program in a patient population at high risk for cardiovascular complications. The investigators will specifically address the novel idea that exercise will not only improve cardiovascular fitness but will also ameliorate the renal complications resulting from diabetes.
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Illinois
-
Hines, Illinois, Verenigde Staten, 60141-5000
- Edward Hines Jr. VA Hospital, Hines, IL
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Diabetes mellitus
- CKD Stages 2-4
- BMI > 30
- Persistent proteinuria (urine protein/creatinine > 200 mg/g for > 3 mo)
- On treatment with ACE inhibitor or ARB
- On treatment with aspirin
- On treatment with statin (if LDL > 100)
Exclusion Criteria:
- Symptomatic neuropathy/retinopathy
- Positive stress test due to coronary arterial disease
- Symptomatic cardiovascular disease
- Congestive heart failure (New York Heart Association Class III or IV)
- Chronic obstructive pulmonary disease (FEV1 < 50% predicted and/or requires supplemental oxygen support during exercise)
- Complaints of angina during the stress test
- Cerebrovascular disease/cognitive impairment
- Renal transplant
- Inability to walk on the treadmill
- Any unforeseen illness or disability that would preclude exercise testing or training
- Participation in a formal exercise program within the previous 12 weeks
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Geen tussenkomst: Controle
Controlegroep
|
|
Experimenteel: Exercise
Exercise Group
|
Exercise training for 12 weeks followed by home exercise for 40 weeks
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Change in Proteinuria
Tijdsspanne: 12 weeks minus baseline
|
12 weeks minus baseline
|
Change in Proteinuria
Tijdsspanne: 52 weeks minus baseline
|
52 weeks minus baseline
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
Change in Albuminuria
Tijdsspanne: 12 weeks minus baseline
|
12 weeks minus baseline
|
Change in Albuminuria
Tijdsspanne: 52 weeks minus baseline
|
52 weeks minus baseline
|
Change in Estimated Glomerular Filtration Rate (eGFR)
Tijdsspanne: 12 weeks minus baseline
|
12 weeks minus baseline
|
Change in Estimated Glomerular Filtration Rate (eGFR)
Tijdsspanne: 52 weeks minus baseline
|
52 weeks minus baseline
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Eileen G. Collins, PhD RN, Edward Hines Jr. VA Hospital, Hines, IL
- Hoofdonderzoeker: David J Leehey, Edward Hines Jr. VA Hospital, Hines, IL
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- F7264-R
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Chronische nierziekte
-
Children's Oncology GroupNational Cancer Institute (NCI)Actief, niet wervendStadium I Nier Wilms-tumor | Stadium II Kidney Wilms-tumor | Stadium III Kidney Wilms-tumor | Stadium IV Kidney Wilms-tumor | Volwassen Nier Wilms-tumor | Beckwith-Wiedemann-syndroom | Kidney Wilms-tumor | Diffuse hyperplastische perilobar nefroblastomatose | Rhabdoïde tumor van de nier | Stadium V Kidney...Verenigde Staten, Canada, Australië, Nieuw-Zeeland, Puerto Rico, Israël
-
Children's Oncology GroupNational Cancer Institute (NCI)VoltooidTerugkerend nierneoplasma bij kinderen | Stadium I Nier Wilms-tumor | Stadium II Kidney Wilms-tumor | Stadium III Kidney Wilms-tumor | Stadium IV Kidney Wilms-tumorVerenigde Staten
-
Children's Oncology GroupNog niet aan het wervenStadium I Nier Wilms-tumor | Stadium II Kidney Wilms-tumor | Stadium III Kidney Wilms-tumor | Stadium IV Kidney Wilms-tumor
-
CAMC Health SystemOnbekendAKI (Acute Kidney Injury) als gevolg van traumaVerenigde Staten
-
Children's Oncology GroupNational Cancer Institute (NCI)WervingStadium II Kidney Wilms-tumor | Stadium III Kidney Wilms-tumor | Stadium IV Kidney Wilms-tumor | Terugkerende Nier Wilms-tumor | Anaplastische Nier Wilms-tumorVerenigde Staten, Canada, Puerto Rico, Australië, Nieuw-Zeeland, Saoedi-Arabië
-
Ain Shams UniversityVoltooidAKI (Acute Kidney Injury) als gevolg van traumaEgypte
-
Children's Oncology GroupNational Cancer Institute (NCI)Actief, niet wervendStadium III Kidney Wilms-tumor | Stadium IV Kidney Wilms-tumorVerenigde Staten, Canada, Australië, Nieuw-Zeeland, Puerto Rico, Israël, Zwitserland
-
Children's Oncology GroupNational Cancer Institute (NCI)Actief, niet wervendStadium I Nier Wilms-tumor | Stadium II Kidney Wilms-tumor | Stadium III Kidney Wilms-tumorVerenigde Staten, Canada, Australië, Nieuw-Zeeland, Puerto Rico, Israël, Zwitserland